Real-world-evidence, prospective-observational study to evaluate safety and effectiveness of rabeprazole dual-delayed-release capsules in patients with gastroesophageal reflux disease

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 1

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Pharmacology and Therapeutics

ISSN

2150-5349

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastrointest Pharmacol Ther. Mar 5, 2025; 16(1): 103898
Published online Mar 5, 2025. doi: 10.4292/wjgpt.v16.i1.103898

Table 6 Nature and association of adverse events during the study

Variables	Frequency	Percentage
Nature of adverse event
Diarrhea	6	26.09
Constipation	4	17.39
Giddiness	3	13.04
Headache	2	8.70
Acidity	2	8.70
Polydipsia	1	4.35
Loose motion	1	4.35
Polyphagia	1	4.35
Fatigue	1	4.35
Dry mouth	1	4.35
Vomiting	1	4.35
Association of adverse events using causality assessment criteria
Related	15	65.22
Unrelated	7	30.43
Possible	1	4.35

Citation: Lawate P, Chauhan V, Prasad LR, Pawar A, Puranik AG, Bansal A, Koganti A, Jaiswal A, Puradkar P, Jhaveri K. Real-world-evidence, prospective-observational study to evaluate safety and effectiveness of rabeprazole dual-delayed-release capsules in patients with gastroesophageal reflux disease. World J Gastrointest Pharmacol Ther 2025; 16(1): 103898
URL: https://www.wjgnet.com/2150-5349/full/v16/i1/103898.htm
DOI: https://dx.doi.org/10.4292/wjgpt.v16.i1.103898

Lawate P, Chauhan V, Prasad LR, Pawar A, Puranik AG, Bansal A, Koganti A, Jaiswal A, Puradkar P, Jhaveri K. Real-world-evidence, prospective-observational study to evaluate safety and effectiveness of rabeprazole dual-delayed-release capsules in patients with gastroesophageal reflux disease. World J Gastrointest Pharmacol Ther 2025; 16(1): 103898 [PMID: 40094149 DOI: 10.4292/wjgpt.v16.i1.103898]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.